{{Rsnum
|rsid=8191439
|Gene=GSTP1
|Chromosome=11
|position=67583826
|Orientation=plus
|GMAF=0.045
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=GSTP1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 1.8 | 98.2
| HCB | 0.0 | 5.1 | 94.9
| JPT | 0.0 | 1.8 | 98.2
| YRI | 0.0 | 5.4 | 94.6
| ASW | 0.0 | 3.5 | 96.5
| CHB | 0.0 | 5.1 | 94.9
| CHD | 0.0 | 7.3 | 92.7
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 2.7 | 97.3
| MEX | 10.3 | 41.4 | 48.3
| MKK | 0.0 | 1.3 | 98.7
| TSI | 0.0 | 1.0 | 99.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs8191439
|Name_s=GSTP1: 5'UTRG(-18)A
|Gene_s=GSTP1
|Feature=5' UTR
|Evidence=PubMed ID:18559526
|Annotation=The variant is located in the promoter region of the GSTP1 gene and was significantly associated with the level of GSTP1 mRNA in Mexican Americans. The G(-18)A variant is tightly linked with the well studied Ile 105 Val polymorphism, which is associated with various clinical phenotypes.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161845829
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}